Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma
Status:
Terminated
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to compare how the drug Sprycel (dasatinib) can
help to control the tumor in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged
Melanoma. The safety of this drug will also be studied.
Objectives:
Primary Objectives:
1. To compare the biological response of tumors With and Without Resectable Tumors from
patients with acral, or mucosal melanomas after treatment with dasatinib.
Secondary Objectives:
1. To assess the safety and tolerability of dasatinib in this patient population
Completely Resectable Acral, Chronic Sun-damaged (CSD), and Mucosal Melanoma:
2. To assess the median time to recurrence and overall survival of patients with completely
resectable acral, CSD, and mucosal melanoma treated with dasatinib
3. To assess whether FDG-avidity and KIT phosphorylation responses after treatment with
dasatinib predicts prolonged time to recurrence and/or overall survival in patients with
completely resectable acral, CSD, and mucosal melanomas
Not Completely Resectable Acral, CSD, and Mucosal Melanoma:
4. To assess the response rate, progression free survival, and overall survival of patients
with acral, CSD, and mucosal melanoma treated with dasatinib
5. To assess whether FDG-avidity and KIT phosphorylation responses after treatment with
dasatinib predicts response rate, progression free survival, and/or overall survival in
patients with acral, CSD, and mucosal melanomas